Avacopan in Patients With Rapidly Progressive Glomerulonephritis Requiring Dialysis
Frank B. Cortazar, Jorge Cerdá, Rahim Dhanani, Joseph Roglieri, Dominick Santoriello
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis with a predilection for the kidney.1 Morbidity and mortality among patients with AAV are largely driven by kidney-related outcomes.2 In particular, the requirement for kidney replacement therapy (KRT) is associated with a marked decrease in patient survival and decreased quality of life.3 Therefore, therapies that can rapidly and effectively treat ANCA-associated glomerulonephritis (GN) have the potential to significantly improve patient outcomes.
Topics & Concepts
MedicineVasculitisANCA-Associated VasculitisDialysisAnti-neutrophil cytoplasmic antibodyGlomerulonephritisRenal replacement therapyRapidly progressive glomerulonephritisKidneyInternal medicineMicroscopic polyangiitisQuality of life (healthcare)Intensive care medicineImmunologyDiseaseNursingVasculitis and related conditionsCoagulation, Bradykinin, Polyphosphates, and AngioedemaRenal Diseases and Glomerulopathies